Alyeska Investment Group
MTCR

Alyeska Investment Group’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Alyeska Investment Group’s Portfolio MTCR Stock Details MTCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-179,782
Closed -$1.11M – 936
2021
Q1 		$1.11M Hold
179,782
– – 0.01% 549
2020
Q4 		$1.41M Sell
179,782
-1,438
-0.8% -$13.2K 0.02% 397
2020
Q3 		$1.85M Buy
+181,220
New +$1.86M 0.03% 360

Other funds holding MTCR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Alyeska Investment Group's MTCR Position: Q2 2021 in Review

Alyeska Investment Group sold out of Metacrine, Inc. Common Stock (MTCR) in Q2 2021, closing a stake of 179,782 shares — an estimated $1.11M sold.

Alyeska Investment Group first reported a position in MTCR in Q3 2020 and held it in 3 quarters. The position peaked at $1.85M in Q3 2020. 42 funds tracked by Wall St. Rank hold MTCR as of Q2 2021.

  • Alyeska Investment Group reported no remaining Metacrine, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Alyeska Investment Group sold 179,782 Metacrine, Inc. Common Stock shares in Q2 2021, an estimated $1.11M.
  • Alyeska Investment Group first reported a position in Metacrine, Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • Alyeska Investment Group's Metacrine, Inc. Common Stock position peaked at $1.85M in Q3 2020.
  • 42 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q2 2021.

Based on Alyeska Investment Group's 13F filing for Q2 2021, filed 16 Aug 2021.